David H. Moore

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Krishnansu S. Tewari, Michael W. Sill, Richard T. Penson et al. · The Lancet · 2017 · 656 citations · Full text

Advanced Cervical Cancer, Cervical Cancer Management, Cervical Cancer +11

Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study

David H. Moore, John A. Blessing, Richard P. McQuellon et al. · Journal of Clinical Oncology · 2004 · 634 citations · Full text

Secondary Surgical Cytoreduction for Advanced Ovarian Carcinoma

Peter G. Rose, Stacy Nerenstone, Mark F. Brady et al. · New England Journal of Medicine · 2004 · 399 citations · Full text

Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group

David H. Moore, Gillian Thomas, Gustavo S. Montana et al. · International Journal of Radiation Oncology*Biology*Physics · 1998 · 313 citations

Vulvar Diseases, Gynecological Surgery, Medicine +8

Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer.

Vincenzo Papa, Biancamaria Gliozzo, Clark Gm et al. · PubMed · 1993 · 252 citations

Breast Oncology, Pathology, Human Breast Cancer +17